Product News

Share this article:
Watson received FDA approval for a generic version of Plan B, Duramed Pharmaceuticals' emergency contraceptive. Watson's generic is approved for prescription only, in women 17 and younger. Duramed retains OTC exclusivity on the product – indicated for women 18 years and older – until August 24, 2009.

FDA did not approve GlaxoSmithKline's Rexonic (casopitant mesylate), an antiemetic. FDA issued a complete response letter containing questions that “preclude the approval of the application,” according to a GSK statement. “[GSK] is reviewing this letter and will engage FDA to determine appropriate next steps,” the statement said.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.